For Healthcare Professionals

Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis

clipboard-pencil

About the study

This is a multi-center, open-label extension (OLE) study in patients with plaque psoriasis who have completed their participation in a previous plaque psoriasis study of ESK-001.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:


  1. Must have completed a prior ESK-001 study
  2. Men and Women must use highly effective methods of contraception for the entirety of the study

EXCLUSION CRITERIA

Exclusion Criteria:


  1. Pregnancy
  2. Received a prohibited concomitant medication

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Plaque Psoriasis

Age (in years)

18+

Phase

PHASE2

Participants needed

165

Est. Completion Date

Dec 30, 2026

Treatment type

INTERVENTIONAL


Sponsor

Alumis Inc

ClinicalTrials.gov identifier

NCT05739435

Study number

ESK-001-007

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.